Combined application of saponin and chimeric toxins drastically enhances the targeted cytotoxicity on tumor cells

被引:58
作者
Heisler, I
Sutherland, M
Bachran, C
Hebestreit, P
Schnitger, A
Melzig, MF
Fuchs, H
机构
[1] Med Univ Berlin, Charite, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany
[2] Free Univ Berlin, Inst Pharm Pharmazeut Biol, D-14195 Berlin, Germany
关键词
recombinant chimeric toxin; immunotoxin; saporin; epidermal growth factor; saponin; cancer therapy;
D O I
10.1016/j.jconrel.2005.04.006
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Immunotoxins have to be administered in high doses due to low cytosolic uptake with the consequence of severe side effects. Recently we found that the cytotoxic activity from Agrostemma githago seeds can be attributed to a synergistic toxicity of a triterpenoid saponin and a ribosome-inactivating protein. Here we investigated whether saponins are able to enhance the efficacy of a receptor-specific chimeric toxin consisting of saporin-3, epidermal growth factor and a molecular adapter previously shown to reduce side effects on non-target cells. Pre-applied saponin enhances the target cell-specific cytotoxic effect, dependent on the cell line, between 3560- and 385,000-fold with an IC50 up to 0.67 pM. Non-target cells are not affected at the same concentration. At the optimal concentrations of the chimeric toxin and saponin application of either one of the components shows no cytotoxicity at all proving a synergistic effect. In the presence of saponin ligand-free saporin-3 does not exhibit any cytotoxic effect up to 0.1 nM providing further evidence for an increased specificity. This synergistic effect is in the same order of magnitude as in a mouse model. Our investigations clearly demonstrate that a combined administration of saponin and chimeric toxins opens up a promising perspective for tumor therapy. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:123 / 137
页数:15
相关论文
共 34 条
[1]   INTERACTIONS OF SOYBEAN LECTIN, SOYASAPONINS, AND GLYCININ WITH RABBIT JEJUNAL MUCOSA INVITRO [J].
ALVAREZ, JR ;
TORRESPINEDO, R .
PEDIATRIC RESEARCH, 1982, 16 (09) :728-731
[2]  
Beerens A. M. J., 2003, Current Gene Therapy, V3, P486, DOI 10.2174/1566523034578258
[3]  
Brinkmann U, 2000, IN VIVO, V14, P21
[4]  
Brusa P, 1997, FARMACO, V52, P71
[5]  
Colombatti M, 2001, METH MOL B, V166, P55
[6]   RESISTANCE OF MYELOID-LEUKEMIA CELL-LINES TO RICIN A-CHAIN IMMUNOTOXINS [J].
ENGERT, A ;
BROWN, A ;
THORPE, P .
LEUKEMIA RESEARCH, 1991, 15 (11) :1079-1086
[7]  
ESPINET ROGER G., 1951, GACETA VET [BUENOS AIRES], V13, P265
[8]   Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment [J].
Falnes, PO ;
Wesche, J ;
Olsnes, S .
BIOCHEMISTRY, 2001, 40 (14) :4349-4358
[9]   Cellular delivery of impermeable effector molecules in the form of conjugates with peptides capable of mediating membrane translocation [J].
Fischer, PM ;
Krausz, E ;
Lane, DP .
BIOCONJUGATE CHEMISTRY, 2001, 12 (06) :825-841
[10]   PRECLINICAL STUDIES WITH THE ANTI-CD19-SAPORIN IMMUNOTOXIN BU12-SAPORIN FOR THE TREATMENT OF HUMAN-B-CELL TUMORS [J].
FLAVELL, DJ ;
FLAVELL, SU ;
BOEHM, DA ;
EMERY, L ;
NESS, A ;
LING, NR ;
RICHARDSON, PR ;
HARDIE, D ;
WRIGHT, DH .
BRITISH JOURNAL OF CANCER, 1995, 72 (06) :1373-1379